Clinical Trials Logo

Gastrointestinal Tumor clinical trials

View clinical trials related to Gastrointestinal Tumor.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06340620 Recruiting - Pancreatic Cancer Clinical Trials

EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope

Start date: March 25, 2024
Phase: N/A
Study type: Interventional

This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract.

NCT ID: NCT05262491 Recruiting - Clinical trials for Gastrointestinal Tumor

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor

Start date: February 14, 2022
Phase: Phase 1
Study type: Interventional

In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-B01D1. In phase Ib study, the safety and tolerability of BL-B01D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be evaluated.

NCT ID: NCT04960943 Recruiting - Effect of Drug Clinical Trials

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

Start date: February 1, 2020
Phase: Phase 2
Study type: Interventional

Targeting human epidermal factor receptor 2 (HER2) therapy have shown the anti-tumor efficacy in patients with HER2-positive gastrointestinal tumors. Pyrotinib is an irreversible small-molecule receptor tyrosine kinase inhibitor targeting both epidermal growth factor receptor (EGFR) and HER2. This study is designed to evaluate the efficacy and safety of Pyrotinib in patients with HER2 positive gastrointestinal tumors.

NCT ID: NCT04960072 Recruiting - Clinical trials for Gastrointestinal Tumor

Study on TIL for the Treatment of r/r Gastrointestinal Tumors

Start date: June 30, 2021
Phase: Early Phase 1
Study type: Interventional

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant refractory/relapsed gastrointestinal tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.